Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Pexa-vec (thymidine kinase-deactivated vaccinia virus plus GM-CSF) in combination with cemiplimab (REGN2810; ANTIPD-1) for metastatic or unresectable renal cell carcinoma REN026: Results from a phase II study
- Authors
- Rha, S. Y.; Bae, W. K.; Kim, C.; Oh, S. Y.; Lee, H. W.; Park, K.; Mar, N.; Kichenadasse, G.; Ha, H. K.; Pachynski, R.; Park, I.; Park, K. H.; Kim, S. H.; Folefac, E.; Mathias, M. D.; Seebach, F.; Ma, S.; Carranza, L.; Beom, S-H.; Merchan, J. R.
- Issue Date
- 202310
- Conference Name
- Annals of Oncology
- Place
- 스페인
Barcelona, SPAIN
- Conference Name
- Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)
- ISSN
- 0923-7534
1569-8041
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 5. Others > ETC > 2. Conference Papers
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Related Researcher
- Park, Kyong Hwa
- Anam Hospital (Department of Medical Oncology and Hematology, Anam Hospital)